Corbus Pharmaceuticals Announces CEO to Participate in Piper Sandler Virtual Oncology Symposium.

Corbus Pharmaceuticals Holdings, Inc. announced that CEO Yuval Cohen will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9, 2025. Corbus is a clinical stage oncology and obesity company with a pipeline including CRB-701 and CRB-601. The company is committed to bringing innovative approaches to well-understood biological pathways to help people defeat serious illness.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has announced that Yuval Cohen, Ph.D., the company's Chief Executive Officer, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium on October 9, 2025. The event, hosted by Biren Amin, Managing Director of Piper Sandler - Healthcare Equity Research, will take place from 10:00 AM ET Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium^[1].

Corbus Pharmaceuticals is a clinical stage oncology and obesity company dedicated to bringing innovative scientific approaches to well-understood biological pathways. The company's pipeline includes CRB-701, a next-generation antibody drug conjugate targeting the expression of Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium^[1].

The company recently received FDA fast track designation for CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD-(L)1 therapy. This designation highlights Corbus's commitment to advancing innovative treatments for serious illnesses Oncology Drugs Granted FDA Designations in September 2025^[2].

Corbus Pharmaceuticals is headquartered in Norwood, Massachusetts, and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.